Valuation: Lexicon Pharmaceuticals, Inc.

Market Cap 1.07B 924M 864M 790M 1.49B 102B 1.51B 10.13B 3.98B 50.95B 4.01B 3.92B 170B P/E 2026 *
-13.8x
P/E 2027 * -12.8x
Enterprise Value 1.07B 924M 864M 790M 1.49B 102B 1.51B 10.13B 3.98B 50.95B 4.01B 3.92B 170B EV / Sales 2026 *
29.4x
EV / Sales 2027 * 53.6x
Free-Float
98.28%
Yield 2026 *
-
Yield 2027 * -
1 day-2.83%
1 week+3.00%
Current month+3.90%
1 month+8.11%
3 months+20.00%
6 months+83.21%
Current year+108.70%
1 week 1.96
Extreme 1.96
2.52
1 month 1.96
Extreme 1.96
2.52
Current year 1.1
Extreme 1.1
2.68
1 year 1.02
Extreme 1.02
2.68
3 years 0.28
Extreme 0.2836
3.73
5 years 0.28
Extreme 0.2836
6.33
10 years 0.28
Extreme 0.2836
19.62
Manager TitleAgeSince
Chief Executive Officer 56 2024-07-07
Director of Finance/CFO 59 2025-01-01
Chief Tech/Sci/R&D Officer - 2025-01-31
Director TitleAgeSince
Chairman 83 2004-12-31
Chairman 71 2012-02-26
Director/Board Member 67 2007-08-27
Date Insider Type Main position Quantity % Market Cap.
2/28/26 Fiscal year

General Counsel

651,031 0.1792%
2/28/26 Fiscal year

Chief Executive Officer

1,211,357 0.3333%
2/28/26 Fiscal year

Chief Financial Officer

375,355 0.1033%
Change 5-day change 1-year change 3-year change Capi.($)
-2.83%+3.00%+122.22%+39.53% 1.1B
+4.21%+25.62%+77.96%+111.62% 68.12B
+0.50%+6.20%+34.94%+67.83% 55.18B
+2.78%+36.87%+23.00%+493.09% 28.63B
+0.57%+18.87%+57.08%+5.18% 23.99B
-0.93%+0.60%-16.89%-12.00% 23.53B
-0.35%+7.91%+44.14%-22.61% 18.45B
-2.04%+10.84%+31.14%+628.97% 16.44B
+7.26%+14.16%+221.03%+393.89% 15.83B
-2.05%-3.81%+40.40%+150.40% 13.4B
Average +0.71%+8.77%+63.50%+185.59% 26.47B
Weighted average by Cap. +1.63%+11.41%+54.29%+164.44%

Financials

2026 *2027 *
Net sales 36.36M 31.48M 29.42M 26.89M 50.67M 3.47B 51.46M 345M 135M 1.73B 137M 134M 5.78B 19.91M 17.24M 16.11M 14.73M 27.75M 1.9B 28.19M 189M 74.14M 950M 74.77M 73.14M 3.16B
Net income -75.12M -65.03M -60.78M -55.55M -105M -7.16B -106M -713M -280M -3.58B -282M -276M -11.94B -90.89M -78.68M -73.54M -67.22M -127M -8.67B -129M -862M -338M -4.34B -341M -334M -14.44B
Net Debt - -
Logo Lexicon Pharmaceuticals, Inc.
Lexicon Pharmaceuticals, Inc., is a biopharmaceutical company. The Company is engaged in research and development of drug candidates and the commercialization of the drug, INPEFA (sotagliflozin). INPEFA reduces the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, chronic kidney disease (CKD), and other cardiovascular risk factors. Sotagliflozin is an orally delivered small molecule drug candidate as a treatment for hypertrophic cardiomyopathy (HCM) and conducts the SONATA-HCM pivotal Phase 3 clinical trial of sotagliflozin in that indication. The Company develops pilavapadin, an orally delivered small molecule drug candidate, as a treatment for neuropathic pain. The Company also develops LX9851, an orally delivered small molecule drug candidate, for the treatment of obesity and associated cardiometabolic disorders.
Employees
81
Date Price Change Volume
26-08-10 US$2.400 -2.83% 2,696,698
26-08-07 US$2.470 +4.66% 3,085,741
26-08-06 US$2.360 -3.67% 4,890,832
26-08-05 US$2.450 -1.61% 3,974,293
26-08-04 US$2.490 +6.87% 3,908,893
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
2.400USD
Average target price
3.856USD
Spread / Average Target
+60.67%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LXRX Stock